Haemostasis I+II.
[Hemosztazeológia I+II.]
EPTIS Ringversuch Nr. 1257381 | Letze Änderung 2024-10-07 | URL: https://www.eptis.bam.de/pts1257381 https://www.eptis.bam.de/pts1257381
| Name des Anbieters | |||||||||||||||||||||||||
| Name des Anbieters | QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd. QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd. | ||||||||||||||||||||||||
| Ansässig in | Hungary | ||||||||||||||||||||||||
| Sprache(n) | English, Hungarian | ||||||||||||||||||||||||
| Anmerkungen | Combined order of scheme 221. and 222. enables favourable participation fee. The evaluation is based on the device and the reagent. In this case 1 set of samples is included for the 2 schemes, in which the parameters of both schemes are involved. The evaluation of the 2 schemes is done separately in scheme 221. and 222. | ||||||||||||||||||||||||
| Klassifizierung | |||||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
Human test material |
||||||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
||||||||||||||||||||||||
| Technische Einzelheiten | |||||||||||||||||||||||||
|
|||||||||||||||||||||||||
| Ringversuchsziele | |||||||||||||||||||||||||
| Zielgruppe des Ringversuchs | In vitro medical laboratories | ||||||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | CLSI GP44-A4 – Procedures for Handling and Processing of Blood Specimens for Common Laboratory Tests ILAC_G8:09/2019 – Guidelines on Decision Rules and Statements of Conformity ISO 15189 – Medical laboratories – Requirements for quality and competence ISO/TS20658:2017 – Medical laboratories – Requirements for collection, transport, receipt and handling of samples VIM3 – Vocabulaire International de Métrologie WHO – Guidance on regulations for the Transport of Infectious Substances | ||||||||||||||||||||||||
| Weitere Ziele | validation of testing methods | ||||||||||||||||||||||||
| Teilnehmerzahl | |||||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch NAH (National Accreditation Authority) auf der Grundlage von ISO/IEC 17043:2010 |
||||||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||||||||||||||||||||
| Kosten | |||||||||||||||||||||||||
| Teilnahmegebühr | on demand | ||||||||||||||||||||||||
| Regelmässig durchgeführt | Ja (six times a year) | ||||||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 1997 | ||||||||||||||||||||||||
| Kontaktdaten des Anbieters | |||||||||||||||||||||||||
| Anbieter | Kontaktperson | ||||||||||||||||||||||||
|
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
Feketesas u. 19-21. I/7 6720 Szeged Hungary Telefon: +36 30 462 5864 Fax: Web: http://www.qualicont.com/qc/index_en.html http://www.qualicont.com/qc/index_en.html |
Ms. Eszter Mezey
Telefon: +36 30 462 5864 Fax: E-Mail: mail@qualicont.com mail@qualicont.com |
||||||||||||||||||||||||